Therapy Areas: AIDS & HIV
Aditxt Signs Amendment to Extend Worldwide Licensing Agreement, Granting Exclusivity in all Fields of Use
30 December 2021 - - US-based biotechnology innovation company Aditxt, Inc (NASDAQ: ADTX) has signed an amendment to its February 3, 2020, exclusive license agreement with Stanford University, extending Aditxt's exclusive right to license the technology deployed in AditxtScore and securing worldwide exclusivity in all fields of use of the licensed technology, the company said.

According to the company, the technology is a highly sensitive and accurate method of detecting and quantifying cellular responses, allowing greater specificity, quantification, and amplification of clinical and commercial opportunities.

The technology underpins the AditxtScore platform, allowing for a standardization of cellular assays.

These assays can then be used as a development platform for clinical utility. Applications of the technology can be used to profile individuals to select appropriate therapies and assess immune status before, during, and after therapeutic intervention.

Aditxt develops technologies focused on improving immune system health through immune monitoring and reprogramming.

Aditxt's immune monitoring technology is designed to provide a personalized, comprehensive system immune system profile.

Aditxt's immune reprogramming technology, currently preclinical, is designed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies.

AditxtScore for COVID-19 is Aditxt's proprietary immune profile technology to equip people with information about their level of protection.


Related Headlines